Comparison · NCT03939637-cd99732c
Experimental: Eltrombopag vs Comparator: Standard Therapy: Proportion of Patients With a Platelet Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Experimental: Eltrombopag vs Comparator: Standard Therapy: Proportion of Patients With a Platelet Response. Trial comparisons, record NCT03939637-cd99732c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03939637-cd99732c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.556 | 0.761 | wilson | |
| Risk in group 2 | 0.35 | 0.221 | 0.505 | wilson | |
| Risk difference, group 1 minus group 2 | 0.317 | 0.127 | 0.476 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.9 | 1.21 | 2.99 | log | |
| Odds ratio, group 1 over group 2 | 3.71 | 1.67 | 8.29 | log | |
| Number needed to treat, for one more participant with the outcome on Experimental: Eltrombopag than on Comparator: Standard Therapy | 3.16 | 2.1 | 7.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Experimental: Eltrombopag | Patients ages 1 to \<18 years with newly diagnosed primary ITP, platelets \<30 x 10\^9/L, requiring pharmacological treatment, but without severe bleeding or need for rapid rise in counts, randomized to receive the experimental therapy (eltrombopag). | 52 | 78 | OG000 |
| Group 2 | Comparator: Standard Therapy | Patients ages 1 to \<18 years with newly diagnosed primary ITP, platelets \<30 x 10\^9/L, requiring pharmacological treatment, but without severe bleeding or need for rapid rise in counts, randomized to receive standard therapy (investigator choice of glucocorticoids, IVIg, anti-D immunoglobulin). | 14 | 40 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Proportion of Patients With a Platelet Response
- Description
To determine if the percentage of patients with a platelet response is significantly greater in patients with newly diagnosed ITP treated with eltrombopag than those treated with standard first-line treatments
- Time frame
- 12 weeks
- Population
- This study included 118 pediatric patients (median age 8y, 49% male), 78 randomized to eltrombopag and 40 to standard therapy.
Source ClinicalTrials.gov
Trial
- Title
- Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
- NCT number
- NCT03939637
- Phases
- PHASE3
- Conditions
- Immune Thrombocytopenia
- Interventions
- Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
- Lead sponsor
- Baylor College of Medicine
- Results first posted
- 2025-07-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03939637?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03939637-cd99732c